Publications by authors named "Milka I Yanachkova"

Dual antiplatelet therapy with aspirin and an adenosine diphosphate (ADP) P2Y receptor antagonist reduces ischemic events in patients with acute coronary syndrome. Previous evidence from our group, obtained in a preclinical model of recurrent platelet-mediated thrombosis, demonstrated that GLS-409, a diadenosine tetraphosphate derivative that inhibits both P2Y and P2Y ADP receptors, may be a novel and promising antiplatelet drug candidate. However, the salutary antiplatelet effects of GLS-409 were accompanied by a trend toward an unfavorable increase in bleeding.

View Article and Find Full Text PDF

Objective: Unlike currently approved adenosine diphosphate receptor antagonists, the new diadenosine tetraphosphate derivative GLS-409 targets not only P2Y12 but also the second human platelet adenosine diphosphate receptor P2Y1 and may, therefore, be a promising antiplatelet drug candidate. The current study is the first to investigate the in vivo antithrombotic effects of GLS-409.

Approach And Results: We studied (1) the in vivo effects of GLS-409 on agonist-stimulated platelet aggregation in anesthetized rats, (2) the antithrombotic activity of GLS-409 and the associated effect on the bleeding time in a canine model of platelet-mediated coronary artery thrombosis, and (3) the inhibition of agonist-stimulated platelet aggregation by GLS-409 versus selective P2Y1 and P2Y12 inhibition in vitro in samples from healthy human subjects before and 2 hours after aspirin intake.

View Article and Find Full Text PDF
Article Synopsis
  • Current platelet ADP receptor antagonists primarily target the P2Y12 receptor, which may not effectively reduce thrombotic events in high-risk patients.
  • Researchers synthesized new P(1),P(4)-di(adenosine-5') tetraphosphate (Ap4A) derivatives to better inhibit platelet aggregation by targeting multiple receptors (P2Y1 and P2Y12) simultaneously.
  • The newly developed analogs show a quicker action and improved stability compared to Ap4A, indicating their potential as a more effective class of antiplatelet agents.
View Article and Find Full Text PDF

P(1),P(2)-Diimidazolyl derivatives of pyrophosphate and halomethylene-bis-phosphonates have been synthesized and characterized, and the mechanism of their formation was studied. These reagents enable synthesis of dinucleoside tetraphosphates and tetraphosphonates conveniently and in high yields.

View Article and Find Full Text PDF